Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of $1.31 billion. The enterprise value is $1.30 billion.
| Market Cap | 1.31B |
| Enterprise Value | 1.30B |
Important Dates
The last earnings date was Thursday, September 24, 2026, after market close.
| Earnings Date | Sep 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 50.80 million shares outstanding. The number of shares has increased by 2.40% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 50.80M |
| Shares Change (YoY) | +2.40% |
| Shares Change (QoQ) | +1.37% |
| Owned by Insiders (%) | 3.97% |
| Owned by Institutions (%) | 15.09% |
| Float | 35.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 99.45 |
| Forward PS | 18.41 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 99.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.44
| Current Ratio | 1.44 |
| Quick Ratio | 1.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.43 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -21.34% |
| Return on Invested Capital (ROIC) | -66.69% |
| Return on Capital Employed (ROCE) | -69.86% |
| Weighted Average Cost of Capital (WACC) | 8.04% |
| Revenue Per Employee | $131,452 |
| Profits Per Employee | -$603,976 |
| Employee Count | 100 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Nanobiotix has paid $14,852 in taxes.
| Income Tax | 14,852 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +37.41% in the last 52 weeks. The beta is 0.57, so Nanobiotix's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +37.41% |
| 50-Day Moving Average | 37.83 |
| 200-Day Moving Average | 33.39 |
| Relative Strength Index (RSI) | 25.06 |
| Average Volume (20 Days) | 145,017 |
Short Selling Information
The latest short interest is 175,987, so 0.47% of the outstanding shares have been sold short.
| Short Interest | 175,987 |
| Short Previous Month | 149,217 |
| Short % of Shares Out | 0.47% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.05 |
Income Statement
In the last 12 months, Nanobiotix had revenue of $13.15 million and -$60.40 million in losses. Loss per share was -$1.25.
| Revenue | 13.15M |
| Gross Profit | 13.15M |
| Operating Income | -33.84M |
| Pretax Income | -60.38M |
| Net Income | -60.40M |
| EBITDA | -34.03M |
| EBIT | -33.84M |
| Loss Per Share | -$1.25 |
Balance Sheet
The company has $126.69 million in cash and $121.80 million in debt, with a net cash position of $4.89 million or $0.10 per share.
| Cash & Cash Equivalents | 126.69M |
| Total Debt | 121.80M |
| Net Cash | 4.89M |
| Net Cash Per Share | $0.10 |
| Equity (Book Value) | -38.14M |
| Book Value Per Share | -0.75 |
| Working Capital | 42.90M |
Cash Flow
In the last 12 months, operating cash flow was -$38.48 million and capital expenditures -$1.14 million, giving a free cash flow of -$39.63 million.
| Operating Cash Flow | -38.48M |
| Capital Expenditures | -1.14M |
| Depreciation & Amortization | -186,874 |
| Net Borrowing | 43.38M |
| Free Cash Flow | -39.63M |
| FCF Per Share | -$0.78 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -257.43% |
| Pretax Margin | -459.35% |
| Profit Margin | n/a |
| EBITDA Margin | -258.87% |
| EBIT Margin | -257.43% |
| FCF Margin | n/a |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.40% |
| Shareholder Yield | -2.40% |
| Earnings Yield | -4.62% |
| FCF Yield | -3.03% |
Analyst Forecast
The average price target for Nanobiotix is $54.00, which is 109.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $54.00 |
| Price Target Difference | 109.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 40.84% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of 2.89 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.89 |
| Piotroski F-Score | 2 |